CurrentUnitedHealthcarePolicy CS054.U

Airway Clearance Devices — High-frequency chest wall oscillation (HFCWO) and related devices

This policy governs medical necessity and coverage for high-frequency chest wall oscillation systems and certain airway clearance devices for UnitedHealthcare members, specifying indications, trial requirements, and devices considered unproven. It affects clinicians prescribing or supplying these devices and prior authorization reviewers.

Policy Summary

PayerUnitedHealthcare

PolicyAirway Clearance Devices — HFCWO and related devices

Policy CodePolicy CS054.U

Change TypeNo material changes

Effective DateApr 1, 2025

Next Review Date

Key ActionRequire an initial two-month rental trial to confirm tolerance and efficacy before ongoing coverage is approved.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

2-monthrequired rental trial duration

49.1% → 24.0%respiratory hospitalization rate (before → after)

15pages

up to 20/secvest frequency

Coverage Criteria and Determinations

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Initial coverage (proven indications)

Covered when ALL of the following are met

Primary coverage criteria for HFCWO: A two-month rental trial of a high-frequency chest wall oscillation (HFCWO) system is required and is considered proven and medically necessary for management of neuromuscular diseases, bronchiectasis, or cystic fibrosis when clinical criteria are met.2-month trial

Ongoing use requires documentation of individual tolerance and efficacy per InterQual criteria; prior authorization should reflect trial start and outcomes.

Coverage summary

Summary of coverage and evidence-based criteria from document segments provided

Combination OLE devices - Not Covered: Combination CPEP, CHFO, and nebulized medication therapy devices for oscillation and lung expansion (OLE) are considered unproven and not medically necessary due to insufficient quality evidence or consistency of findings.

Explicit policy determination in document.

HFCWO evidence — supportive but limited: Multiple randomized trials, cohort studies, registry analyses, and systematic reviews report mixed results: some short-term physiologic or patient-reported improvements and reductions in hospitalizations in pre/post studies, but trials are small, heterogeneous, and at risk of bias; therefore evidence supports limited, indication-specific coverage with required trial.

Document emphasizes need for larger, well‑designed RCTs and refers reviewers to InterQual for ongoing-use determinations.

Coverage considerations

Consider coverage when clinical context and evidence align with proposed benefits:

Postoperative high-risk patients: Consider OLE therapy in high‑risk postoperative patients where nonrandomized prospective data showed reduced postoperative pulmonary complications, ventilator time, and hospital length of stay (Huynh et al.; 419 subjects), but require well‑documented clinical rationale and prospective evidence where possible.

Authors call for randomized trials to confirm benefit.

Neuromuscular weakness with impaired cough: Consider HFCWO for patients with neuromuscular disease when airway clearance is clinically indicated and guideline thresholds are met (e.g., peak cough flow <270 L/min or maximal expiratory pressure <60 cm H2O); HFCWO has been used in these populations though data to make a formal recommendation are limited.peak cough flow <270 L/min OR maximal expiratory pressure <60 cm H2O

Consistent with ATS recommendations to use assisted cough technologies and mechanical insufflation‑exsufflation; document need for assisted clearance and expected benefit.

Chronic airway diseases (CF, bronchiectasis, COPD):

Not medically necessary / Unproven devices and indications

Devices considered unproven/not medically necessary: HFCWO is not medically necessary for conditions other than neuromuscular diseases, bronchiectasis, and cystic fibrosis; combination CPEP/CHFO/nebulized OLE devices and intrapulmonary percussive ventilation (IPV) devices for home use are considered unproven and not medically necessary.

Refer to InterQual for additional clinical coverage criteria and to support adjudication of requests for these devices.

Combination therapies that pair continuous positive expiratory pressure (CPEP), continuous high-frequency oscillation (CHFO), and nebulized medication delivery—collectively described as oscillation and lung expansion (OLE) devices—have been evaluated but lack consistent, high-quality evidence of clinical benefit. The policy designates these combined CPEP/CHFO/nebulized-therapy devices as unproven; because available studies are heterogeneous and limited in quality, such combination OLE devices are considered not medically necessary.

The policy explicitly states that combination CPEP/CHFO/nebulized medication therapy devices intended for OLE and intrapulmonary percussive ventilation (IPV) devices for home use are unproven and not medically necessary. Requests for these combination devices should be reviewed with the expectation that coverage is unlikely in the absence of robust, disease-specific supporting evidence.

Systematic reviews and meta-analyses report that trials of oscillatory airway clearance devices are generally small, heterogeneous, and at risk of bias, with overall evidence quality rated from low to very low. As a result, the policy does not endorse any specific device as clearly superior for cystic fibrosis or bronchiectasis; comparative studies show few consistent differences between oscillatory devices and other airway clearance techniques.

High-frequency chest wall oscillation (HFCWO) is supported for a limited set of conditions. The policy recognizes HFCWO as proven and medically necessary only when used for management of neuromuscular diseases, bronchiectasis, and cystic fibrosis after meeting clinical criteria and completing an initial trial. Use of HFCWO outside these indications remains unproven due to insufficient evidence of benefit.

To restate the policy position: devices that combine CPEP, CHFO, and nebulized medication for OLE are considered not medically necessary because the current body of evidence is insufficient in quality and consistency to demonstrate meaningful clinical benefit.

Intrapulmonary percussive ventilation (IPV) studies are limited, heterogeneous, and provide mixed results across disease states. Systematic reviews conclude that evidence for IPV as a routine airway clearance technique is insufficient to support widespread adoption; IPV is therefore considered unproven and not medically necessary for home use unless compelling, disease‑specific justification is provided.

Applicable Codes and Billing Details

Applicable HCPCS/CPT/Device CodesHCPCS

A7021	Supplies and accessories for lung expansion airway clearance, continuous high frequency oscillation, and nebulization device (e.g., handset, nebulizer kit, biofilter).
A7025	High frequency chest wall oscillation system vest, replacement for use with patient-owned equipment, each.
A7026	High frequency chest wall oscillation system hose, replacement for use with patient-owned equipment, each.
E0469	Lung expansion airway clearance, continuous high frequency oscillation, and nebulization device.
E0481	Intrapulmonary percussive ventilation system and related accessories.
E0483	High frequency chest wall oscillation system, with full anterior and/or posterior thoracic region receiving simultaneous external oscillation, includes all accessories and supplies, each.

Applicable ICD-10 Codes (examples listed)ICD-10

A80.0	Acute paralytic poliomyelitis, vaccine-associated.
B91	Sequelae of poliomyelitis.
E74.02	Pompe disease.
E84.0	Cystic fibrosis with pulmonary manifestations.
G12.0	Infantile spinal muscular atrophy, type I [Werdnig-Hoffman].
G12.21	Amyotrophic lateral sclerosis.
J47.9	Bronchiectasis, uncomplicated.
J47.1	Bronchiectasis with (acute) exacerbation.
Z99.11	Dependence on respirator [ventilator] status.

Device product codemixed

BYI	FDA product code referenced for The Vest/high-frequency chest wall oscillation devices

Initial trial duration — HFCWO

Initial trial durationTwo-month (2-month) rental trial required to confirm individual tolerance and efficacy before ongoing medical necessity is determined

Purpose of trialEstablish individual tolerance and efficacy of HFCWO prior to approval of ongoing coverage

Reference for ongoing useOngoing medical necessity determination should refer to InterQual criteria after the rental trial

Prior Authorization, Rental Trials, and Documentation

Prior Authorization

Initial two-month rental trial required

For all indications, an initial two-month rental trial of a high-frequency chest wall oscillation (HFCWO) or oscillation and lung expansion (OLE) system is required to confirm individual tolerance and clinical benefit before ongoing coverage is considered. The rental trial documents efficacy (symptom reduction, sputum clearance, reduced exacerbations or healthcare utilization) and tolerance; failure to complete or document a trial may result in denial of ongoing coverage.

Initial rental trial duration: 2 months (rental)
Trial must demonstrate tolerance and objective/subjective benefit to support continuation

Prior Authorization

Rental trial step — confirm tolerance and efficacy

A rental trial (initial trial period) must be used to confirm that the member can tolerate the device and that the device provides clinical benefit prior to approval of ongoing durable medical equipment (DME) coverage. Documentation from the trial should include the treating physician’s assessment of benefit, member-reported outcomes, and any objective measures used (e.g., exacerbation frequency, sputum production, pulmonary function where applicable).

Rental trial purpose: confirm tolerance and efficacy
Documentation should include treating physician’s assessment and objective/subjective measures

Step Therapy

Stepwise use of airway clearance techniques (ACTs)

When considering airway clearance therapies, clinicians are expected to use a stepwise approach and trial alternative techniques because no single airway clearance technique (ACT) has consistently demonstrated superiority across conditions. Reasonable clinical practice is to document prior trials of other ACTs (e.g., PEP, ACBT, autogenic drainage, directed coughing, oscillatory PEP devices) and the member’s response before proceeding to HFCWO/OLE.

Document prior trials of alternative ACTs and clinical response
No consistent evidence that one ACT uniformly outperforms others

Note

Consideration of alternative airway clearance techniques

Given the lack of clear superiority of HFCWO/OLE over other ACTs in the literature, it is reasonable to consider alternative airway clearance techniques prior to or during evaluation for HFCWO/OLE. Trialing alternatives and documenting inadequate response supports medical necessity for escalation to HFCWO/OLE.

Trial and document alternatives when clinically appropriate (PEP, ACBT, O-PEP, manual techniques)
Rationale: comparative studies show mixed or low-certainty evidence

Denial Risk

Combination OLE devices — coverage stance

Combination devices that integrate continuous positive expiratory pressure (CPEP), continuous high-frequency oscillation (CHFO), and nebulized medication delivery for oscillation and lung expansion (OLE) are considered unproven and not medically necessary due to insufficient and inconsistent quality evidence. Requests for combination OLE devices should be denied or subject to noncoverage unless compelling, high-quality evidence is provided.

Combination CPEP/CHFO/nebulized OLE devices — considered unproven and not medically necessary
Deny coverage or require additional high-quality evidence for combination devices

Note

Supporting documentation from observational studies

Some observational and cohort studies report reductions in healthcare utilization (hospitalizations, pneumonia claims) and costs after initiation of HFCWO in neuromuscular disease populations; however, these studies lack randomized concurrent controls and have limitations (administrative data, potential selection bias). Such observational evidence may support clinical rationale but is insufficient alone to establish efficacy for indications beyond those specified as medically necessary.

Observational evidence (e.g., pre/post claims cohorts) suggests reduced hospitalizations and costs after HFCWO initiation in NMD patients
Limitations: no concurrent control groups, potential confounding — supportive but not definitive

Documentation Required

OLE for postoperative pulmonary complication reduction — evidence and stance

OLE (combination oscillation and lung expansion) has been evaluated in non-randomized and observational postoperative studies showing reduced postoperative pulmonary complications and resource use in some cohorts, but evidence is observational and inconsistent. Well-designed prospective controlled trials are needed; until then, postoperative use of OLE should be considered investigational or limited to contexts where the treating physician documents rationale and expected benefit.

OLE postoperative studies: observational findings of reduced PPCs, ventilator time, and LOS in some cohorts
Recommendation: consider investigational or limited use pending stronger controlled trial evidence

Documentation Required

Coding and documentation requirements

Coding and documentation must be provided to support medical necessity determinations and claims. Use the listed HCPCS codes and ensure relevant ICD-10 diagnosis codes and clinical records are included with prior authorization or claim submission.

Relevant HCPCS: A7021, A7025, A7026, E0469, E0481, E0483
Include treating physician’s clinical notes, diagnosis (ICD-10) codes, rental trial documentation, and prior therapy trials

Definitions and Device Descriptions

Bronchiectasis — definition and clinical radiographic criteria

DefinitionBronchiectasis is a chronic respiratory disease characterized by dilation (ectasia) of the airways or bronchi, associated with recurrent, chronic, or refractory infections

Clinical criteriaClinically significant bronchiectasis has at least two of: cough most days of the week; sputum production most days of the week; history of exacerbations

Radiographic confirmationPresence of bronchiectasis is confirmed and classified radiographically by high-resolution, spiral, or standard computed tomography (CT) scan

Combination OLE devices — definition

DefinitionCombination OLE devices are systems that combine Continuous Positive Expiratory Pressure (CPEP), Continuous High Frequency Oscillation (CHFO), and nebulized medication therapy for oscillation and lung expansion (OLE)

Policy stanceThese combination CPEP/CHFO/nebulized OLE devices are considered unproven and not medically necessary due to insufficient quality evidence or consistency of findings

Implication for prior authorizationRequests for these combination devices are likely to be denied or require additional justification and evidence

High-frequency chest wall compression (HFCWO) — device description and indication summary

Device descriptionHigh-frequency chest wall compression (HFCWO) devices deliver external oscillatory compressions to the chest wall via a vest and air-pulse generator to promote airway clearance and bronchial drainage

Indication summaryIndicated when external chest manipulation is the physician's treatment of choice to enhance mucus transport

Device referenceFDA product code BYI is referenced for HFCWO devices (see FDA PMN website)

Intrapulmonary percussive ventilation (IPV) — definition and brief evidence note

DefinitionIntrapulmonary percussive ventilation (IPV) is a ventilatory technique that delivers high-frequency percussive breaths (mini-bursts) intended to mobilize secretions and improve ventilation

Evidence summaryRCTs and systematic reviews report mixed results: some small RCTs show improvements in symptoms and select physiologic outcomes, but overall evidence is limited and not uniformly supportive

Policy implicationUse of IPV as an airway clearance technique is not supported by sufficiently strong evidence for widespread adoption and may be considered unproven or not medically necessary without disease-specific justification

Oscillation and lung expansion (OLE) — definition and intended postoperative application

DefinitionOscillation and lung expansion (OLE) refers to combination therapies using continuous high-frequency oscillation and continuous positive expiratory pressure often delivered with adjunct nebulized medication to promote lung expansion and secretion clearance

Intended applicationOLE has been evaluated for reducing postoperative pulmonary complications and improving lung expansion in high-risk surgical patients in non-randomized studies

Evidence and coverage stanceCombination OLE devices (CPEP+CHFO+nebulization) are considered unproven and not medically necessary due to insufficient quality evidence and inconsistent findings

OpenPayer

Airway Clearance Devices — High-frequency chest wall oscillation (HFCWO) and related devices

Coverage Criteria and Determinations

Applicable Codes and Billing Details

Prior Authorization, Rental Trials, and Documentation

Clinical Background and Evidence Overview

Definitions and Device Descriptions